Literature DB >> 24496335

Glycogen phosphorylase isoenzyme BB, creatine kinase isoenzyme MB and troponin I for monitoring patients with percutaneous coronary intervention - a pilot study.

Milan Skitek1, Igor Kranjec, Aleš Jerin.   

Abstract

AIM: The glycogen phosphorylase isoenzyme BB (GPBB), as an ischemic marker, has not yet been investigated after elective percutaneous coronary intervention (PCI). ose aim of the study was to monitor GPBB, creatine kinase myocardial isoform (CK-MB) mass) and troponin I (TnI) value after PCI in correlation with ischemic incidents.
METHODS: Forty-two consecutive patients undergoing elective PCI were included in the study. Baseline blood samples and two more after the PCI (3 and 24 hours) were taken. The significance of cardiac markers in twenty-ththe stable patients with baseline values of CK-MB mass and TnI below the upper reference limit (URL) was evaluated based on ischemic incidents after PCI.
RESULTS: TnI value was the only biomarker that was statistically significant at 3 and 24 hours after PCI in group of 23 stable patients. An overall comparisonthe biomarkers of 18 patients without and five patients with ischemic incidents displayed significant differences only for the baseline GPBB (p=0.019) and CK-MB mass 24 hours after PCI (p=0.034). Ischemic incidents were independently predictable only based on overall CK-MB mass measurements (OR=1.680, p=0.041) and particularly GPBB at baseline (OR=1.899, p=0.008) and CK-MB mass 24 hours after PCI (OR=2.111, p=0.022).
CONCLUSIONS: Only significant increases in TnI were observed after elective PCI with ischemic incidents predicted using GPBB and CK-MB mass measurements.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24496335

Source DB:  PubMed          Journal:  Med Glas (Zenica)        ISSN: 1840-0132


  1 in total

1.  The effect of adenosine triphosphate on propofol-induced myopathy in rats: a biochemical and histopathological evaluation.

Authors:  Kezban Tuna Ozkaloglu Erdem; Zehra Bedir; Irem Ates; Ufuk Kuyrukluyildiz; Taha Abdulkadir Coban; Gulce Naz Yazici; Yusuf Kemal Arslan; Zeynep Suleyman; Halis Suleyman
Journal:  Korean J Physiol Pharmacol       Date:  2021-01-01       Impact factor: 2.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.